UA85359C2 - Таблетка, содержащая гранулированный материал с kmd-3213 - Google Patents

Таблетка, содержащая гранулированный материал с kmd-3213

Info

Publication number
UA85359C2
UA85359C2 UAA200809667A UAA200809667A UA85359C2 UA 85359 C2 UA85359 C2 UA 85359C2 UA A200809667 A UAA200809667 A UA A200809667A UA A200809667 A UAA200809667 A UA A200809667A UA 85359 C2 UA85359 C2 UA 85359C2
Authority
UA
Ukraine
Prior art keywords
kmd
pharmaceutically acceptable
tablet containing
granulated material
containing granulated
Prior art date
Application number
UAA200809667A
Other languages
English (en)
Ukrainian (uk)
Inventor
Цуйоси Наганума
Мицуо Мурамацу
Original Assignee
Киссеи Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85359(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Киссеи Фармасьютикал Ко., Лтд. filed Critical Киссеи Фармасьютикал Ко., Лтд.
Publication of UA85359C2 publication Critical patent/UA85359C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA200809667A 2002-12-16 2003-12-11 Таблетка, содержащая гранулированный материал с kmd-3213 UA85359C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16

Publications (1)

Publication Number Publication Date
UA85359C2 true UA85359C2 (ru) 2009-01-12

Family

ID=32588229

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200507046A UA84694C2 (ru) 2002-12-16 2003-12-11 Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов
UAA200809667A UA85359C2 (ru) 2002-12-16 2003-12-11 Таблетка, содержащая гранулированный материал с kmd-3213

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA200507046A UA84694C2 (ru) 2002-12-16 2003-12-11 Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов

Country Status (23)

Country Link
US (2) US20060018959A1 (ru)
EP (2) EP1574215B1 (ru)
JP (1) JP4633469B2 (ru)
KR (2) KR101077061B1 (ru)
CN (2) CN100339078C (ru)
AU (1) AU2003289320C1 (ru)
BR (1) BR0317349A (ru)
CA (1) CA2507002C (ru)
EA (1) EA008196B1 (ru)
ES (1) ES2544560T3 (ru)
HR (1) HRP20050544B1 (ru)
IL (1) IL169040A (ru)
IS (1) IS7929A (ru)
ME (2) MEP10808A (ru)
MX (1) MXPA05006513A (ru)
NO (1) NO20053467L (ru)
NZ (1) NZ540664A (ru)
PL (1) PL220457B1 (ru)
RS (1) RS58025B1 (ru)
TW (2) TWI325318B (ru)
UA (2) UA84694C2 (ru)
WO (1) WO2004054574A1 (ru)
ZA (1) ZA200504613B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167511A1 (en) * 2004-03-05 2007-07-19 Kissei Pharmaceutical Co,. Ltd. Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
CN101027052A (zh) * 2004-10-05 2007-08-29 橘生药品工业株式会社 用于伴下尿路梗阻的集尿障碍的预防和/或治疗剂
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
AR065698A1 (es) * 2007-03-13 2009-06-24 Takeda Pharmaceutical Preparacion solida
ES2471076T3 (es) 2010-06-28 2014-06-25 Ratiopharm Gmbh Compuestos de inclusión de silodoxina-ciclodextrina
JP2013532651A (ja) 2010-07-23 2013-08-19 ラティオファルム ゲー・エム・ベー・ハー シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
EP2474529B1 (en) 2010-12-23 2014-05-14 Sandoz AG Crystalline forms of an active pharmaceutical ingredient
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
WO2013061338A1 (en) 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
JP6215238B2 (ja) * 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
JP6491093B2 (ja) 2012-07-16 2019-03-27 フィブロジェン インコーポレイテッド プロリルヒドロキシラーゼ阻害剤の結晶形態
TWI659752B (zh) 2013-03-26 2019-05-21 日商橘生藥品工業股份有限公司 經遮蔽西羅多辛(Silodosin)苦味之經口投與製劑
DK3003284T3 (da) 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
KR102206104B1 (ko) 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法
CN114601826B (zh) * 2022-03-31 2024-06-04 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
DE69319551T2 (de) * 1992-12-02 1998-10-29 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
NZ283160A (en) 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AU9095998A (en) * 1997-09-22 1999-04-12 Kissei Pharmaceutical Co. Ltd. Remedies for dysuria resulting from prostatic hypertrophy
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α1Aアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
AU2001256714A1 (en) * 2000-05-15 2001-11-26 Kissei Pharmaceutical Co. Ltd. Water-based liquid preparation
SI1413331T1 (sl) * 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
KR101072909B1 (ko) 2011-10-17
TW200418457A (en) 2004-10-01
BR0317349A (pt) 2005-11-16
MEP10808A (en) 2010-06-10
JP4633469B2 (ja) 2011-02-16
AU2003289320C1 (en) 2018-09-06
ES2544560T3 (es) 2015-09-01
JPWO2004054574A1 (ja) 2006-04-20
KR20100133024A (ko) 2010-12-20
EA008196B1 (ru) 2007-04-27
IL169040A (en) 2013-04-30
TWI382838B (zh) 2013-01-21
KR101077061B1 (ko) 2011-10-26
EP1574215A1 (en) 2005-09-14
UA84694C2 (ru) 2008-11-25
EP1574215A4 (en) 2009-07-01
US20120064154A1 (en) 2012-03-15
HRP20050544A2 (en) 2006-09-30
NZ540664A (en) 2007-09-28
ZA200504613B (en) 2006-08-30
RS20050470A (sr) 2007-09-21
HK1107768A1 (en) 2008-04-18
CA2507002A1 (en) 2004-07-01
PL220457B1 (pl) 2015-10-30
HK1085131A1 (en) 2006-08-18
NO20053467L (no) 2005-07-15
CN101069685A (zh) 2007-11-14
EA200500985A1 (ru) 2005-12-29
IS7929A (is) 2005-07-01
AU2003289320B2 (en) 2008-08-21
HRP20050544B1 (hr) 2017-12-01
ME00076B (me) 2011-02-10
US20060018959A1 (en) 2006-01-26
AU2003289320A1 (en) 2004-07-09
TW200944200A (en) 2009-11-01
KR20050084316A (ko) 2005-08-26
PL377495A1 (pl) 2006-02-06
RS58025B1 (sr) 2019-02-28
CN1726028A (zh) 2006-01-25
CN100339078C (zh) 2007-09-26
WO2004054574A1 (ja) 2004-07-01
TWI325318B (en) 2010-06-01
EP2402010A1 (en) 2012-01-04
EP1574215B1 (en) 2015-07-15
CA2507002C (en) 2012-09-18
CN101069685B (zh) 2011-12-14
MXPA05006513A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
IL101162A0 (en) Pharmaceutical compositions for oral administration comprising an indole derivative
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
SE9901573D0 (sv) New compounds
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
NO20051709L (no) Kystallforbindelse for fast oralt medikament samt fast oralt medikament omfattende denne til behandling av dysuria
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
TW200503775A (en) Pharmaceutical composition and method for treating
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
RU2003100507A (ru) Фармацевтические композиции
JPWO2004066998A1 (ja) 安定な経口用固形医薬組成物
UA86782C2 (ru) Применение галоидного производного гидроксамовой кислоты в лечении нейродегенеративных заболеваний центральной нервной системы
JP2020125330A (ja) 縮合アミノジヒドロチアジン誘導体の医薬組成物
EA202193065A1 (ru) Фармацевтическая композиция, содержащая акситиниб
WO2000066550A8 (en) New compounds
TW200517127A (en) Novel composition
CN103002893A (zh) 神经障碍性疼痛的治疗药或预防药
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives